BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simone CB, Houshmand S, Kalbasi A, Salavati A, Alavi A. PET-Based Thoracic Radiation Oncology. PET Clinics 2016;11:319-32. [DOI: 10.1016/j.cpet.2016.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Rice SR, Saboury B, Houshmand S, Salavati A, Kalbasi A, Goodman CR, Werner TJ, Vujaskovic Z, Simone CB 2nd, Alavi A. Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy. Nucl Med Commun 2019;40:618-25. [PMID: 31095527 DOI: 10.1097/MNM.0000000000000997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Menon H, Guo C, Verma V, Simone CB 2nd. The Role of Positron Emission Tomography Imaging in Radiotherapy Target Delineation. PET Clin 2020;15:45-53. [PMID: 31735301 DOI: 10.1016/j.cpet.2019.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Verma V, Schonewolf CA, Cushman TR, Post CM, Doms A, Berman AT, DeVries M, Katz SI, Simone CB 2nd. Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19:502-10. [PMID: 30111509 DOI: 10.1016/j.cllc.2018.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Song YQ, Wang N, Qiao Y, He L, Li X, Zhang XF, Yang QK, Wang RZ, He R, Wang CY, Ren YW, Li G, Wang TL. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis. J Cancer Res Clin Oncol 2020;146:1021-31. [PMID: 31980929 DOI: 10.1007/s00432-020-03134-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Simone CB 2nd, Sawant A. Margins and Uncertainties in Radiation Oncology. Semin Radiat Oncol 2018;28:169-70. [PMID: 29933875 DOI: 10.1016/j.semradonc.2018.03.001] [Reference Citation Analysis]
6 Verma V, Choi JI, Sawant A, Gullapalli RP, Chen W, Alavi A, Simone CB. Use of PET and Other Functional Imaging to Guide Target Delineation in Radiation Oncology. Seminars in Radiation Oncology 2018;28:171-7. [DOI: 10.1016/j.semradonc.2018.02.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
7 Choi JI, Simone CB 2nd. Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer. J Thorac Dis 2018;10:130-4. [PMID: 29600039 DOI: 10.21037/jtd.2017.12.79] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zou W, Dong L, Kevin Teo BK. Current State of Image Guidance in Radiation Oncology: Implications for PTV Margin Expansion and Adaptive Therapy. Semin Radiat Oncol 2018;28:238-47. [PMID: 29933883 DOI: 10.1016/j.semradonc.2018.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
9 Schonewolf CA, Verma V, Post CM, Berman AT, Frick MA, Vachani A, Lin C, Simone CB. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Lung Cancer 2018;117:53-9. [DOI: 10.1016/j.lungcan.2017.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Verma V, Shostrom VK, Kumar SS, Zhen W, Hallemeier CL, Braunstein SE, Holland J, Harkenrider MM, S. Iskhanian A, Neboori HJ, Jabbour SK, Attia A, Lee P, Alite F, Walker JM, Stahl JM, Wang K, Bingham BS, Hadzitheodorou C, Decker RH, Mcgarry RC, Simone CB. Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors. Cancer 2016;123:688-96. [DOI: 10.1002/cncr.30375] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
11 Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C, Hahn SM, Dorsey JF, Simone CB 2nd. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys 2018;102:536-42. [PMID: 30244877 DOI: 10.1016/j.ijrobp.2018.06.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
12 Berman AT, Jabbour SK, Vachani A, Robinson C, Choi JI, Mohindra P, Rengan R, Bradley J, Simone CB 2nd. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res 2019;8:5-14. [PMID: 30788230 DOI: 10.21037/tlcr.2018.12.12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
13 Ke L, Wu L, Yu J, Meng X. Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy. Nucl Med Commun 2021;42:1017-23. [PMID: 33899782 DOI: 10.1097/MNM.0000000000001428] [Reference Citation Analysis]
14 Ke L, Wang L, Yu J, Meng X. Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study. Front Oncol 2021;11:652312. [PMID: 34094942 DOI: 10.3389/fonc.2021.652312] [Reference Citation Analysis]
15 Dreyfuss AD, Jahangiri P, Simone CB 2nd, Alavi A. Evolving Role of Novel Quantitative PET Techniques to Detect Radiation-Induced Complications. PET Clin 2020;15:89-100. [PMID: 31735305 DOI: 10.1016/j.cpet.2019.08.003] [Reference Citation Analysis]
16 Jahangiri P, Pournazari K, Torigian DA, Werner TJ, Swisher-McClure S, Simone CB 2nd, Alavi A. A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Eur J Nucl Med Mol Imaging 2019;46:206-16. [PMID: 30229527 DOI: 10.1007/s00259-018-4154-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
17 Algranati C, Strigari L. Imaging Strategies in Proton Therapy for Thoracic Tumors: A Mini Review. Front Oncol 2022;12:833364. [DOI: 10.3389/fonc.2022.833364] [Reference Citation Analysis]
18 Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB 2nd, Siegel BA, Machtay M, Alavi A. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 2017;44:1969-83. [PMID: 28689281 DOI: 10.1007/s00259-017-3753-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]